SureTrader Advertisement
Home > Boards > Canadian > Biotechs >

Trillium Therapeutics Inc. (TRIL)

TRIL RSS Feed
Add TRIL Price Alert      Hide Sticky   Hide Intro
Moderator: NY1972
Search This Board:
Last Post: 7/26/2016 4:48:34 PM - Followers: 32 - Board type: Free - Posts Today: 1

Trillium Therapeutics Inc. (NASDAQ:TRIL, TSX:TR)

Home: http://trilliumtherapeutics.com/trillium-home/default.aspx

 

Trillium Therapeutics Inc. 
2488 Dunwin Drive 
Mississauga, Ontario, 
Canada L5L 1J9 
Tel: +1 416.595.0627

 

Trillium Therapeutics is an immuno-oncology company dedicated to the discovery and development of novel and innovative cancer therapies. We have two premier pre-clinical programs, SIRPαFc and a CD200 monoclonal antibody, which target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system. 

 

SEC filings:  http://www.nasdaq.com/symbol/tril/sec-filings

 

Twitter:  https://twitter.com/search?q=%24TRIL&src=ctag

 

Quote:  https://www.google.com/finance?q=NASDAQ%3ATRIL&ei=dWJkV-kHiKV5wPiX4As

 

Canadian Insider:  https://www.canadianinsider.com/company?menu_tickersearch=tr

 
Currency Converter: http://www.bankofcanada.ca/en/rates/converter.html


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

 

Last update 6/17/2016

 

Rules of the board according to IHUB:
http://www.investorshub.com/boards/complex_terms.asp

 

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TRIL
Current Price
Volume:
Bid Ask Day's Range
SureTrader
TRIL News: Report of Foreign Issuer (6-k) 06/07/2016 07:21:19 AM
TRIL News: Report of Foreign Issuer (6-k) 05/31/2016 07:36:22 AM
TRIL News: Report of Foreign Issuer (6-k) 05/18/2016 05:01:38 PM
TRIL News: Report of Foreign Issuer (6-k) 05/13/2016 07:12:23 AM
TRIL News: Report of Foreign Issuer (6-k) 04/21/2016 07:02:25 AM
PostSubject
#280   Figuring TRIL will have something to say at RockRat 07/26/16 04:48:34 PM
#279   Mechanisms of Melanoma Resistance to PD-1 Checkpoint Inhibition NY1972 07/24/16 09:58:37 PM
#278   Diverse Roles of Macrophages in Atherosclerosis NY1972 07/21/16 11:02:26 PM
#277   Intravenous treatment with the anti-CD47 treatment reduced by NY1972 07/21/16 09:06:18 PM
#276   CD47 expression is significantly increased in human atherosclerotic plaque NY1972 07/21/16 10:14:40 AM
#275   http://www.nature.com/nature/journal/vaop/ncurrent/full/nature18935.html?WT.ec_i ronpopeil 07/20/16 08:49:46 PM
#274   TNF-alpha-driven CD47 overexpression prevents macrophages from clearing dying NY1972 07/20/16 08:35:11 PM
#273   Therapeutic targeting of SIRPa-CD47 interactions NY1972 07/18/16 11:12:46 PM
#272   Why TRIL is a good pick in IO space NY1972 07/16/16 11:35:34 PM
#271   Immuno-Oncology: The Strategic Supernova NY1972 07/16/16 04:52:16 PM
#270   Mutations Associated with Acquired Resistance to PD-1 Blockade NY1972 07/14/16 10:33:02 PM
#269   Effimune NY1972 07/14/16 04:45:16 PM
#268   Bromodomain Inhibition By OTX015 Regulates c-MYC and HEXIM1 NY1972 07/14/16 10:47:08 AM
#267   Levels of Myc expression correlated strongly with expression NY1972 07/13/16 04:36:03 PM
#266   how is this related to tril? ronpopeil 07/13/16 11:49:24 AM
#265   CUDC-907 Decreases MYC Protein Levels in DLBCL Cells NY1972 07/13/16 11:40:23 AM
#264   Keytruda's chart from Hammer's blog: NY1972 07/13/16 10:24:21 AM
#263   Keytruda NY1972 07/12/16 10:16:47 PM
#262   3/6 centers recruiting, CELG and TRIL are in NY1972 07/11/16 10:32:46 PM
#261   Thrombospondin-1 type I repeats (3TSR) - Knockdown of NY1972 07/10/16 12:34:12 PM
#260   ABT 510 is a Thrombospondin-1 (TSP-1) mimetic drug NY1972 07/10/16 12:02:14 PM
#259   HL:Targeting the Tumor Microenvironment as a Therapeutic Strategy NY1972 07/08/16 11:33:10 PM
#258   PLX3397 for patients with tenosynovial giant-cell tumors NY1972 07/08/16 09:49:34 PM
#257   Will tti-621 do better than PLX3397? NY1972 07/08/16 09:39:04 PM
#256   3 young patients died out of 20 patients NY1972 07/08/16 12:44:10 PM
#255   TSP1 http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0013442 NY1972 07/08/16 12:14:42 PM
#254   How much your share you holding super trades investor_matt 07/07/16 01:09:48 PM
#253   Great tech....massive potential ..... but TRIL has horrible super_trades 07/07/16 09:52:07 AM
#252   20K traded, today's volume is less than CMO's NY1972 07/06/16 04:01:03 PM
#251   When is the ASH abstract expected? investor_matt 07/06/16 02:26:10 PM
#250   Seems like ASH could be a huge pivotal ronpopeil 07/02/16 03:34:06 PM
#249   CELG should have data by ASH, they found NY1972 07/02/16 12:11:50 PM
#248   Will celgene have any data prior to ash? ronpopeil 07/02/16 07:55:27 AM
#247   Trading volume is low because many are waiting NY1972 07/01/16 11:27:02 PM
#246   Hey NY1972, investor_matt 07/01/16 09:49:06 PM
#245   Targeting SIRP alpha, not CD47 NY1972 07/01/16 08:37:21 PM
#244   Most common irAEs including rash, colitis, hepatitis, endocrinopathies, NY1972 06/30/16 10:43:06 PM
#243   Target Preclinical Phase I NY1972 06/30/16 12:21:17 AM
#242   Cancer Moonshot Summit NY1972 06/29/16 09:55:49 AM
#241   Moderna and Merck will develop personalized cancer vaccines NY1972 06/29/16 09:29:02 AM
#240   TRIL is a baby panda in the bear market. NY1972 06/27/16 01:49:26 PM
#239   TRIL bearish 8.64 stocktrademan 06/27/16 01:07:25 PM
#238   Hoping you are right. This is scary. Stock ronpopeil 06/27/16 10:51:08 AM
#237   Best buying op. thanks to Brexit. NY1972 06/27/16 10:50:11 AM
#236   Save a few pounds if you buy TRIL NY1972 06/24/16 11:24:59 AM
#235   how cancer spreads in the body NY1972 06/23/16 09:46:07 AM
#234   0 shares traded at 10 AM! MMs on NY1972 06/21/16 10:04:14 AM
#233   ABBV paid $5B for Rova-T NY1972 06/13/16 10:46:53 PM
#232   Anti CD47 stimulate macrophage-mediated destruction of SCLC NY1972 06/13/16 09:50:57 PM
#231   PD1 combos NY1972 06/12/16 11:57:28 PM
PostSubject